Applied Therapeutics (APLT) Stock Price, News & Analysis

Company Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.38 to $0.39
• 50-Day Range: $0.30 to $0.60
• 52-Week Range: $0.30 to $10.62
• Volume: 885,552 shs
• Average Volume: 3.34 million shs
• Market Capitalization: $53.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.10
• Consensus Rating: Moderate Buy

Applied Therapeutics Stock Analysis - MarketRank™

Applied Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 215th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Applied Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Applied Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.61% of the float of Applied Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Applied Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Applied Therapeutics has recently increased by 25.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied Therapeutics does not currently pay a dividend.

Dividend Growth

Applied Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Percentage of Shares Shorted

18.61% of the float of Applied Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Applied Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Applied Therapeutics has recently increased by 25.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.90

News Sentiment

Applied Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Applied Therapeutics this week, compared to 9 articles on an average week.

Search Interest

Only 5 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

2 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,561.00 in company stock.

Percentage Held by Insiders

Only 8.60% of the stock of Applied Therapeutics is held by insiders.

Percentage Held by Institutions

98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APLT Stock Analysis - Frequently Asked Questions

How have APLT shares performed this year?

Applied Therapeutics' stock was trading at $0.8562 on January 1st, 2025. Since then, APLT shares have decreased by 56.0% and is now trading at $0.3771.
View the best growth stocks for 2025 here.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) released its quarterly earnings results on Monday, April, 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.06. The business earned $0 million during the quarter, compared to analyst estimates of $0.61 million.

When did Applied Therapeutics IPO?

Applied Therapeutics (APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' top institutional shareholders include Propel Bio Management LLC (7.97%), T. Rowe Price Investment Management Inc. (7.33%), Alyeska Investment Group L.P. (2.19%) and Charles Schwab Investment Management Inc. (0.45%). Insiders that own company stock include Real Estate Equitie Alexandria, Shoshana Shendelman, Riccardo Perfetti, Leslie D Funtleyder and Stacy J Kanter.
View institutional ownership trends.

How do I buy shares of Applied Therapeutics?

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 4/14/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APLT
• CIK: 1697532
• Web: www.appliedtherapeutics.com
• Phone: (212) 220-9226
• Fax: N/A
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Stock Price Target: $6.10
• High Stock Price Target: $14.00
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +1,517.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.76 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -260.75%
• Return on Assets: -76.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.06
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $265,000.00
• Price / Sales: 201.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.20) per share
• Price / Book: -1.89

Miscellaneous

• Outstanding Shares: 141,576,000
• Free Float: 106,349,000
• Market Cap: $53.39 million
• Optionable: Optionable
• Beta: 2.00